Funding Wizard

This Funding Opportunity Announcement (FOA) solicits applications from eligible institutions to develop a?Research Coordinating Center (RCC) to support the development of an NIH CCH Community of Practice by managing and supporting current and future CCH research and capacity building efforts. The RCC will create a robust inclusive CCH-COP that fosters collaboration, capacity building, innovation and research that aligns with the NIH CCH initiative. The RCC will offer opportunities for collaboration between multiple disciplines required to conduct solutions-driven research on the health impacts of climate change. The four functions of the RCC are administrative oversight, resource development, data management, and research capacity building.

This FOA invites applications to participate in a research program cooperative agreement to support the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC3H-IN). The Network will expand successes achieved by PATC3H to new geographic settings with limited implementation science (IS) research capacity and/or risk populations who are poorly represented in international adolescent HIV research (e.g. sexual and gender minorities; commercial sex workers; drug users) and stimulate much needed IS research in a neglected area of public health significance: prevention of new HIV infections among adolescents at risk and the identification of, and linkage and retention to care of and long-term viral suppression among youth living with HIV in low-to-middle income countries (LMICs). These settings must have an HIV epidemic density defined by UNAIDS estimates as either a country 1) in which at least 200,000 people are living with HIV and the number has not decreased by more than 5% over the last 2 consecutive years of available data or 2) has an HIV incidence among youth ages 10 to 24 years of 0.01% or more.

This Funding Opportunity Announcement (FOA) invites applications to participate as a Research Center as part of the Maternal Health Research Centers of Excellence initiative. The purpose of this initiative is to generate innovative approaches to address preventable maternal mortality, decrease severe maternal morbidity, and promote maternal health equity in partnership with communities that are most affected (i.e., Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations). This initiative will use an integrated multi-level approach encompassing social and biobehavioral research strategies to address the multiple contributing factors that lead to adverse maternal health outcomes and health disparities. Significant contributing factors include comorbid conditions (e.g., hypertension, diabetes, mental illness, and substance use disorders) and social determinants of health, which include structural racism and health care system factors. The goal of this initiative is for trans-disciplinary researchers to conduct multi-layered novel research approaches that will have the potential to drastically reduce pregnancy-related and pregnancy-associated maternal deaths and decrease severe maternal morbidity. Studies may be interventional (including effectiveness, comparative effectiveness, optimization, or dissemination and implementation studies), or observational (including health services studies, natural experiments, policy analyses) and may assess both short-term and long-term maternal health outcomes. The Research Centers will be uniquely poised to collaborate on studies and projects with other networks and initiatives such as the NICHD Neonatal Research Network and the NICHD Maternal and Pediatric Precision in Therapeutics (MPRINT) initiative.

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support for the Center for International Blood and Marrow Transplant Research (CIBMTR) as a data resource enabling broad studies on Hematopoietic Stem Cell transplantation (HCT) and Adoptive Cellular Therapy (ACT) research. The CIBMTR represents a network comprised of more than 380 US and international transplant centers that submit outcome data for patients receiving cellular therapies. The CIBMTR Statistical Center provides data acquisition and management and information technology services to maintain a unique contemporary clinical outcomes' database and facilitates observational and interventional research through scientific and statistical expertise necessary to support analyses of these data. NIH is supporting the CIBMTR to ensure the database remains available to the public and to improve the treatment, survival, and quality of life for patients diagnosed with cancer and non-malignant blood disorders.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that develop, test, implement, and evaluate behavioral tobacco cessation interventions for adolescents, with a focus on the critical developmental risk period of mid- to late-adolescence (approximately 14-20 years old).

Sleep and circadian dysfunctions are frequently co-morbid with opioid use disorder (OUD) and may have clinical utility in identifying individuals at risk for poor treatment response and relapse. The goals of this program are a) to uncover novel mechanisms underlying the bidirectional interrelationship between sleep/circadian rhythm and OUD, and b) to reveal new insights into sleep and/or circadian-based predictors of OUD medication treatment response and outcomes.

The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid and/or psychostimulant use disorders and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline.

The goal of this Funding Opportunity Announcement (FOA) is to establish Omics Production Center(s) (OPC(s)) that will be part of a collaborative initiative to advance the application of multi-omic technologies to study health and disease in diverse populations. Together with the Disease Study Sites (RFA-HG-22-008) and the Data Analysis and Coordination Center (RFA-HG-22-010), the Omics Production Center(s) will leverage clinical conditions where multi-omic approaches are expected to be most informative to: 1) explore the use of multi-omics, integrated with phenotypic and environmental exposure data, including social determinants of health (SDOH), to detect and assess molecular profiles associated with healthy and disease states; 2) develop generalizable data harmonization, integration, and analysis methods, as well as best practices and standards for the optimal application of multi-omics; and 3) create a multi-dimensional dataset that is available to the research community. The OPC(s) will be primarily responsible for using high high-throughput molecular assays to produce omics data from the biosamples provided by the Disease Study Sites (DSS, RFA-HG-22-008) and contributing to consortium-wide protocol development, data analysis, methods development, and the production of the multi-dimensional dataset. While this program may provide some insights into disease etiology, its primary goal is to validate and enhance generalizable multi-omic approaches to identify meaningful biological changes related to health and disease.

This Funding Opportunity Announcement (FOA) seeks grant applications from small business concerns (SBCs) to develop psychoplastogenic compounds and related models for drug discovery and drug development for Substance Use Disorders (SUD), excluding alcohol use disorder.